Regeneron's Otarmeni Gene Therapy Accepted for EMA Review Under Accelerated Assessment
REGN sits 35% above its 52-week low of $476.487.
Summary
Regeneron's gene therapy, Otarmeni, has received EMA filing acceptance for review under Accelerated Assessment for genetic hearing loss. This is a significant regulatory step towards potential market authorization in the European Union for a first-in-class therapy for an ultra-rare condition. The news follows the FDA's accelerated approval of Otarmeni in the U.S. in April 2026, expanding the drug's global regulatory progress.
At the time of this announcement, REGN was trading at $642.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.